AETERNA ZENTARIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.52 CAD | -0.95% |
|
-0.17% | +12.06% |
| May. 17 | Aeterna Zentaris Finalizes Some Details for Ceapro Merger | MT |
| May. 17 | Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro | MT |
| Sales 2022 | 5.64M 7.7M | Sales 2023 | 4.5M 6.14M | Capitalization | 9.41M 12.85M |
|---|---|---|---|---|---|
| Net income 2022 | -22M -30.04M | Net income 2023 | -16M -21.85M | EV / Sales 2022 | -6.21 x |
| Net cash position 2022 | 50.43M 68.86M | Net cash position 2023 | 33.74M 46.07M | EV / Sales 2023 | -5.41 x |
| P/E ratio 2022 |
-0.68
x | P/E ratio 2023 |
-0.57
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aeterna Zentaris Inc.
More recommendations
More press releases
More news
| 1 day | -0.95% | ||
| 1 week | -0.17% | ||
| Current month | +10.77% | ||
| 1 month | +8.68% | ||
| 3 months | +12.94% | ||
| 6 months | +6.27% | ||
| Current year | +12.06% |
1 week
11.45
11.69
1 month
10.4011.98
Current year
9.1212.72
1 year
7.6416.92
3 years
7.64138.00
5 years
7.64463.00
10 years
7.6416 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 19-10-03 | |
| Director of Finance/CFO | - | 22-01-23 | |
Patricia Zahn
ADM | Chief Administrative Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gilles Gagnon
BRD | Director/Board Member | 70 | 19-12-31 |
Peter Edwards
BRD | Director/Board Member | 62 | 20-05-14 |
Dennis Turpin
BRD | Director/Board Member | - | 21-05-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 11.52 | -0.95% | 721 |
| 24-05-27 | 11.63 | -0.51% | 100 |
| 24-05-23 | 11.69 | +1.30% | 314 |
Delayed Quote Toronto S.E., May 28, 2024 at 03:57 pm EDT
More quotes
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
Calendar
2024-07-01
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +12.06% | 10.35M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
- Stock Market
- Equities
- AEZS Stock
